Market Place
Sourcing Support
Lumos Pharma & Double Point Complete Tender Offer, Acquisition
12 Dec 2024 //
GLOBENEWSWIRE
Phase 2 OraGrowtH Data Show LUM-201’s Impact on PGHD Growth
21 Nov 2024 //
GLOBENEWSWIRE
Lumos Pharma Presents Two Abstracts Accepted at ESPE 2024
30 Oct 2024 //
GLOBENEWSWIRE
Lumos Pharma Merges with Double Point Ventures to Go Private
23 Oct 2024 //
GLOBENEWSWIRE
Lumos Pharma Abstract Accepted For APPES 2024 Presentation
25 Sep 2024 //
GLOBENEWSWIRE
Lumos Pharma Abstract Accepted For SLEP 2024 Presentation
05 Sep 2024 //
GLOBENEWSWIRE
Lumos Pharma Joins H.C. Wainwright Global Investment Conference
15 Aug 2024 //
GLOBENEWSWIRE
Lumos Pharma Reports Q2 2024 Results And Clinical Update
01 Aug 2024 //
GLOBENEWSWIRE
Lumos Pharma To Report Q2 2024 Results On August 1
23 Jul 2024 //
GLOBENEWSWIRE
Lumos Pharma: OraGrowtH212 Phase 2 Data At ENDO 2024
04 Jun 2024 //
GLOBENEWSWIRE
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
20 May 2024 //
GLOBENEWSWIRE
Lumos Pharma Announces Positive FDA End-of-Phase 2 Meeting, Q1 2024 Results
14 May 2024 //
GLOBENEWSWIRE
Lumos Pharma Q1 2024 Results On May 15, Clinical Update
09 May 2024 //
GLOBENEWSWIRE
Lumos Pharma Abstracts Accepted At Upcoming Medical Meetings
18 Apr 2024 //
GLOBENEWSWIRE
Lumos Announces that the USPTO Has Granted Patent Novel Formulation of LUM-201
20 Mar 2024 //
GLOBENEWSWIRE
Lumos Pharma Reports Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Lumos Pharma to Report Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Lumos Pharma to Participate in Oppenheimer™s 34th Annual Conference
05 Feb 2024 //
GLOBENEWSWIRE
Lumos Pharma Promotes Pisit œDuke Pitukcheewanont, MD to Chief Medical Officer
04 Jan 2024 //
GLOBENEWSWIRE
Lumos Pharma to Host Virtual Key Opinion Leader Webinar
21 Nov 2023 //
GLOBENEWSWIRE
Lumos Pharma Announces Participation in Piper Sandler 35th Annual Conference
20 Nov 2023 //
GLOBENEWSWIRE
Lumos stock rockets on oral growth hormone phase 2 results
08 Nov 2023 //
FIERCE BIOTECH
Lumos Pharma Announces Data from Phase 2 Trials of LUM-201
07 Nov 2023 //
GLOBENEWSWIRE
Lumos Pharma Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Lumos Pharma Announces New Data and Analysis of 15 Subjects
26 Sep 2023 //
GLOBENEWSWIRE
Lumos Pharma Announced Abstract Accepted for Oral Presentation at Annual Meeting
14 Sep 2023 //
GLOBENEWSWIRE
Lumos Pharma Announces Participation in Investor Conferences in September
07 Sep 2023 //
GLOBENEWSWIRE
Panel of Pediatric Endocrinologists to Discuss Growth Hormone Deficiency
22 Aug 2023 //
GLOBENEWSWIRE
Lumos Pharma Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Lumos Pharma to Report Second Quarter 2023 Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
12 Jul 2023 //
GLOBENEWSWIRE
Lumos Pharma Announces Departure of Chief Medical Officer
28 Jun 2023 //
GLOBENEWSWIRE
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023
21 Jun 2023 //
GLOBENEWSWIRE
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention
31 May 2023 //
GLOBENEWSWIRE
Lumos Announces Accepted for Presentation at 2023 ENDO Meeting
25 May 2023 //
GLOBENEWSWIRE
Lumos Pharma to Participate in World Orphan Drug Congress USA
22 May 2023 //
GLOBENEWSWIRE
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual (PES)
08 May 2023 //
GLOBENEWSWIRE
Lumos Pharma Reports 1Q 2023 Financial Results, Provides Clinical Updates
03 May 2023 //
GLOBENEWSWIRE
Data from Lumos Pharma OraGrowtH Trials to be Presented at PES
27 Apr 2023 //
GLOBENEWSWIRE
Lumos Pharma to Report 1Q 2023 FYR and Host Conference Call on May 3, 2023
19 Apr 2023 //
GLOBENEWSWIRE
Lumos to Participate in Oppenheimer 33rd Annual Healthcare Conference
09 Mar 2023 //
GLOBENEWSWIRE
Additional Data on Lumos OraGrowtH Trials Presented at Meeting
05 Mar 2023 //
GLOBENEWSWIRE
Lumos Pharma Reports Full Year 2022 FY, Provides Clinical Devp Updates
01 Mar 2023 //
GLOBENEWSWIRE
Lumos Completes Patient Enrollment in PII OraGrowtH Trials Evaluating LUM-201
28 Feb 2023 //
GLOBENEWSWIRE
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call
15 Feb 2023 //
GLOBENEWSWIRE
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access
03 Jan 2023 //
GLOBENEWSWIRE
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Oral Therapeutic
12 Dec 2022 //
GLOBENEWSWIRE
Lumos to Host KOL Webinar to Discuss Phase 2 Data from OraGrowtH Trials
29 Nov 2022 //
GLOBENEWSWIRE
Lumos to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Lumos` oral growth hormone drug falls short of Novo injectable
15 Nov 2022 //
FIERCEPHARMA
Lumos Pharma Announces Interim Results from Two Ph2 Trials Oral LUM-201
14 Nov 2022 //
GLOBENEWSWIRE
Lumos Pharma Reports 3Q 2022 Financial Results and Clinical Development Updates
14 Nov 2022 //
GLOBENEWSWIRE
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
26 Sep 2022 //
GLOBENEWSWIRE
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global
31 Aug 2022 //
GLOBENEWSWIRE
Lumos Pharma Announces Share Repurchase Program
16 Aug 2022 //
GLOBENEWSWIRE
Lumos Pharma Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Lumos Pharma to Report Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Lumos Pharma to Participate in Upcoming Investor Conferences
16 May 2022 //
GLOBENEWSWIRE
Lumos Pharma Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Lumos Pharma Announces a Clinical Collaboration with MGH to Evaluate LUM-201
05 May 2022 //
GLOBENEWSWIRE
